In addi tion to the Reinke's edema, strobovideolaryngoscopy shows a mass on the lower lip of the lef t vibratory margin and severa l large blood vessels. On the right, a perpendi cular blood vessel (not very visible) is present ; its location is p robably the site of a previo us inj ury.
A 5 1-yea r-old adve rtising age nt with a 30-pack -year smoking history comp lained of dyspho nia. She had bee n "hoarse" for a long time, but she hadn' t sought treatment until she lost her voice during a "very social" vacation that involved a great deal of smoking, club dancing, and loud talking. Her voice had not returned to normal.
On examination, the patient 's voice was diplophonic and deeper than norm al. Stro bovideolaryngoscopy revea led a large area of Reinke's ede ma on the right vocal fold and a more generalized edema of the left fold (figure).
The patient was started on acid suppress ion therapy, and she was counseled to stop smoki ng and instructed on proper vocal tech nique by our voice team. A thyroid evaluation was normal.
If conservative measures fail to restore satisfac tory vocal quality and endurance in patient s with Reinke's edema, the swelling can be reduced by incising the epithelium, suc tioning out the polypoid material, and conservatively resec ting the redun dant mucosa.Pulsed dye laser treatment may be helpful in some cases.
Thefollowing treatment-related adverseeventswere each reported in a single patient: ty~~anos tomy tube blockage; ear pruritus; tinni tus; oral monilia sis; cryi ng; dizziness; and eryt hema..Acute~t l t . I S Externa:The followingtreatm ent-related adverse events occurredin 0.4% or more of the patientsWith Intact tympamc membranes.~~: t~~~~c Effects. Pregn ancy Cat egory C: Reproduction studies have been performed ĩ rats and mice using oral doses of up to 100 mg/kg and IV dosesup to 30 mg/kg and have revealed no evidence of harm to the fetus as a result of ciprofloxacin. In rabbits, ciprofl oxacin (30 and 100 m g / k~orally) produced gastrointestinal di sturbances resultingin maternal weight loss and an increased incidence of abortion, but noteratogenicitywasobserved at either dose..After int ravenous administration of do~~s upto 20mg /kg. no maternal toxi city was produced In the .rabblt, and no e.mbryotoxlClty o r . t~r at o g emc l ty~as observed.
Corticosteroids are generallyteratogemc10 laboratoryammals whenadmi nistered svstemicallv at relatively lowdosage levels. The morep~t en t corticosteroids have been shown tobeteratogen.lc afte r derma l application inlaboratoryanimals.Ammal reproduction studieshave not been conducted WIth CIPRODEX Otic. Noadequate andwellcontrolledstudies have been performedinpregnantwomen.Cautionshould be exercisedwhen CIPROOEX" Otic is usedby a pregnant woman. NursingMothers:Ciprofloxacin andcorticosteroids , asa class, appear inmilk followingoraladministration, Dexamethasone in breast milk could suppress growth, interfere withendogenous corticostero idproduction or cause other untoward effects. It is not known whether topical otic administrationofciprofloxacin or dexamethasone could result in suffi cient systemic absorption to produce detectable quantities in human milk. Becau se ofthe pot ential forunwanted effectsin nursing infants, a deci sion should bemade whetherto discontinue nursi ngorto discontinuethedrug, taking into account the importance ofthedrug to themother. Pediatric Use: The safety and efficacy of CIPROOEX" Ot ic have been established in pediatric patients 6 months and older(937patients)in adequate andwell-cont rolled chmca l trials. Althoughnodata are availabl e onpatient sless than age 6 months, therearenoknown safety concerns or differencesInthedisease process inthis populationthat wouldprecl udeuseofthis product (See DOSAGE AND ADMINISTRATION.) Noclinically relevantchangesin hearing functionwereobservedIn 69 pediatric pati entslage4to 12years) treatedwith CIPROOEX" Otic andtestedfor audiometric parameters. ADVERSE REACTIONS In Phases II and III clinical trials, a total of 937 patientswere treated with CIPRO OEX" Ot ic. Thi s included 400patients with acute otitis media with ty m p a nost~my tubes and 537 patients with acute otitis ext ema. The reported treatment-relatedadverseeventsare listedbelow: Acute Ol ilis Media in pediatric pati ents with 1'( mpanostomy tubes: The following treatment-related adverseevent s occurredin 0.5% or moreof the pati ent sWith non-intact tympanic membranes.
The followingtreatment-related adve rse eventswere each reported In a Single patient: ear discomfort; decreased hearing; andear disorder Itinglingl. DOSAGE AND ADMINISTRATION CIPROOEX" OTIC SHOULD BESHAKEN WELL IMMEDIATELY BEFORE USE CIPROOEX" Ot ic cont ains3 mg/ mL13000~g/mL ) ciprofloxacin and 1mg/ mL dexamethasone. Acute OtitisMedia inpedi atricpatients withtympanostomytubes:The recomm endeddosage regimen for the treatmentof acute otitis media in pediatric pat ient s (age 6 months and older) through tympanostomy tubesis: Four drops (0.14 ml, 0.42m~ciproll oxacin, 0.14mgdexamethasone)instilled intothe affected ear twice daily for seven days. Thesolution should bewarmed byholding the bottle Inthe hand for oneor two minut es to avoid dizziness, which mayresult from the instillationof a cold soluti on. Thepati ent should lie with the affect ed ear upward, and then the drops shoul d beinstill ed. The t!agus should then be pumped 5 times by pushing inward to facilitate penetration of the drops Into the middle ear. ThisPOSition should be maintained for 60 seconds. Rep eat.if necessary, for the opposite ear. Discard unused portion after therapyis completed. Acute Otitis Ext erna: The recomm endeddosage regimen for thetreatment of acute otitis externais: Forpatients lage 6 months and older): Four drops 10.14rnl, 0.42 mgciprofloxacin, 0.14 mg dexameth asone) instilled intothe affected ear twice daily for seven days. Thesolution should bewarmed byholding the bott le in thehandfor oneor two minutes to avoid dizziness, whichmayresult fromthe instillation of a coldsolution. The patientshould lie withthe aflected ear upward. andthenthe drop~should be instilled. Thispositionshould bemai ntainedfor 60secondsto facilitate penetratron of thedrops mtotheear canal. Repeat,if necessary, fortheopposite ear. Discard unused portion after therapy is comp leted.
HOW SUPPLIED CI PROOEX"lciprofioxacin 0.3% anddexamethasone0.1%1Sterile Otic Suspension is supplied as follows: 5 mL fill and 7.5 mL fill in a OROP-TAINER" system. The ORO P-T AINER" system consists of a natural polyethylene bottle and natural plug, with a white polypropyl ene closure. Tamper evi dence is provided with a shrink band around the closure and neckarea of the packag e. NOC 0065-8533-01 , 5 mL fill; NOC 0065-8533-02 , 7.5mLfill. Storage: Store at controll edroom temperature, W Cto 30'C (59'F to 86' F) . Avoid freezing. Protect fromlight Clinical Studies: In a randomized, mult icenter, controlled clinical trial, CIPROOEX" Ot ic dosed 2 times per day for 7 days demonstrated clini cal cures in the per protocol analysis in 86% of AOMT patient s compared to 79% for olloxacin sol ution, 0.3%, dosed 2 times per day for 10 days. Among culture positive pati ents, clinical cures were 90% for CIPROOEX" Ot ic comp ared to 79%.tor ofloxacin solution, 0.3%. Microbiological eradication rates for these patients In the same clinical trial were 91% for CIPROOEX" Otic compared to 82% for ofloxacin solution, 0.3%. In 2 randomized mul ticenter, controlled clinical trials, CIPROOEX" Otic dosed 2 times per day for 7 days demonstrated clinical cures in 87% and 94% of per protocol evaluable AO E patients, respectively, compar ed to 84% and 89%, respectively, for otic suspension containing neomycin 0.35%, polymyxin B 10 ,000 IU/mL, and hydrocortisone 1.0% Ineo/pol y/HC). Among cul ture positive pati ents clinical cures were86% and 92% for CIPROOEX" Otic compared to 84% and 89%, respectively. for neo/poly/HC. Microbiological eradication ratesforthesepatients inthesame clinicaltrials were86%and92%for CIPROOEX" Dtic comparedto 85% and85%, respectively, forneo/poly/HC. Pharmacol. 1986; 30:225-230. ("tYOPROOEX l c iro l l o x ac i n~. J % a n~~Bx a mBt n a s on B. orticosteruid, dexamethasone, in a sterile, preserved suspension for otic use. Each mL of CIPRODEX Otic containsciprofloxacin hydrochlori de (equivalent to 3 mgciprofloxacin base), 1 mg dexamethasone, and 0.1mgbenzalkonium chlorideasa preservative.The inactiveingredient s are boric acid, sodium chloride, hydroxyethyl cellulose, tyloxapol, acetic acid, sodium acetate, edetate disodium, and purified water. Sodiumhydroxideor hydrochloric acid maybeaddedfor adjustment of pH.
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Ciprofloxacin, a fluoroquinolone is available as the monohydrochloride monohydrate salt of l-cvclopropyl-6-fluoro-l ,4-dihydro-4-oxo-7-(1-piperazi nyl)-3-quinol inecarboxyli c acid. The empi rical formul a is C17HI8FN30JHCI ·H20. Dexamethasone, 9-fluoro-ll1beta).17,21-trihydroxy-16Ialpha)-methylpregna -l, 4-diene-3,20-dione, is an anti-inflammatory corticosteroid. The empiricalformul a is C22H29F05.
CLINICAL PHARMACOLOGY
Pharmacokinetics: Followinga single bilateral4-dropItotal dose = 0.28 rnl, 0.84mg ciprofloxacin,0.28 mg dexamethasonel topical otic dose of CIPROOEX' Otic to pediatric patients alter tympanostomytubeinsertion, measurableplasma concentrati onsof cipr ofl oxacin and dexamethason e were observed at 6 hours following administrationin 2 of9 patients and5 of 5 pati ents, respecti vely. Mean ± SO peak plasma concentrations of ciprofloxac in were 1. 39 e 0.880 ng/mL In=9). Peak plasma concentr ations ranged from 0.543 ng/mL to 3.45 ng/mL and were on average approximately 0.1% of peak pl asma concentrations achieved with an oral dose of 250-mg lSi. Peak plasma concentrations of ciprofloxacinwereobs ervedwithin 15minutes to2 hours postdose application. Mean ± SOpeak plasma concentrations of dexamethasonewere 1.1 4± 1. 54 ng/mLIn=9). Peak plasma concentrations ranged from 0.135 ng/mLto 5.10 ng/mL and were on average approximately 14% of peak concentrationsreported in the literature following an oral 0.5-mg tabletdose'", Peakplasma concentrations ofdexamethaso newere observedwithin 15minutes to 2hours postdoseapplication. Dexamethasone hasbeen added to aidinthe resolution ofthe inflamm atory response accompanying bacterial infection lsuch as oto rrheain pedi atric pati entswith ADM withtympanostomytubes). Microbiology: Ciprofloxacin hasin vitro activity against a wide range ofgram-positive and gram-negative microorganisms. The bactericidal actionofciprof loxacin results from interferencewith the enzyme, DNA gyrase, which is needed for the synt hesis of bacter ial DNA.Cross-resist ancehas been observed between ciprofloxacin and other fluoroqu inolones. There is gen erallyno cross-resistance between ciprofloxacin and otherclassesof antibacter ial agents suchasbeta-lactams oraminoglycosides. Ciprofloxacin has been shown to be active against mostisolates of the following microorganisms, both in vitro andclinically in otic infect ions asdescribedintheINDICATIONS ANDUSAGE section. 
PRECAUTIONS
General: Aswith other antibacterial prepa rations,use of thi s productmayresult in overgrowth ofnonsuscept ibleorganisms , includingyeast and fungi. If the inf ectionisnotimproved after one weekoftreatment. culturesshouldbeobtained togui defurther treat ment. Ifotorrheapersistsafter a full courseof therapy,or if twoormore episodes ofotorrhea occur within sixmonths,furtherevaluationisrecomm endedtoexclude an underlying condition such as cholesteatoma, foreign body, or a tumor. The systemic administratio n of quinolones, including cip rofloxacin at doses much higher than given or abso rbed bythe otic route, has led to lesions or erosions ofthe cartilagein weight-bearingjoints and other signs of arthropathy in immature animals of various species. Guineapigs dosed in the middle earwith C I P R O D EX~Otic for one month exhibitednodrug-relatedstructural or functiona l changes of the cochlearhaircells andnolesions in the ossicle s. CIPRO OEX " Otic was also shown to lack dermal sensitizing potential in the guinea pig whentestedaccordi ngto themethodof Buehler. Nosigns of local irritationwere foundwhenCIPROOE XÕ ticwas applied topically inthe rabbit eye. Informationfor Patients: Forotic use onlv.Ilhis product is not approved forusein theeye.) Warm the bottle in you r hand forone to twominutesprior to use and shake well immediately before using. Avoid contaminating thetip withmaterial from the ear, fingers, or other sources. Protect from light. If rash or allergic reaction occurs, discontinue use immediately and contact your physician. It is veryimportant to use the ear drops for aslong asthe doctor has instructed, even if the symptomsimprove. Discardunu sedportion aftertherapy is completed. Acute Otitis Media in pediatric patients with tympanostomy tubes: Prior to administration of CIPROOEX" Oticin patients (6months and older)with acute otitis media through tympanosl omy tubes. the solution should be warmed by holdi ng the bottle in the hand for one or two minutes to avoid dizziness whichmay result from theinstillationof a coldsolution. The pat ientshould lie with the affect ed earupward, and thenthe drops should beinstilled. The tragus shoul d then be pumped 5 times by pushing inward to faci litate penetration of the dropsinto the middle ear. This positionshoul d be maintainedfor 60seconds. Repeat, if necessary, for the opposite ear (see DOSAGE AND ADMINISTRATION ). Acute Otit is Externa: Prior to administration of CIPROOEX " Otic in pati ents with acute otitis externa, the sol ution should be warmed by holding the bottle in the hand for one or twominutesto avoid dizziness whi ch may resul t fromthe instillation of a cold solution. The pat ient should lie with the affected ear upward, and thenthe drops should be insti lled. Thi s position should be maintained for60 seconds to facilitate penetration of the drops into the ear canal. Repeat.if necessary, forthe opposite ear (seeDOSAGE AND ADMINISTRATION). Drug Interactions: Specific drug interaction studies have not been conducted with CIPROOEX" Otic. Carcinogenesis, Mutagenesis. Impairment of Fertility: Long-term carci nogenicity studies in mice and rats have been completed for ciprolloxacin. Alter dai ly oral doses of 750 mg/kg Imice) and 250 mg/kg (rats) were adminis tered for up to 2 years, there was no evi dence that ciprofloxacin had any carcinogenic or tumorigenic effects in these spe cies Fertility studies perform ed in rats at oral doses of ciprolloxacinupto 100 mg/kg/day revealed noevidence of impairment This would be over 100 times the maximum recommended clini cal dose ofototopical ciprofloxacin based uponbody surface area,assumingtotal absorptionof ciprofloxacin from the earof a patienttreated with CIPROOEX" Oti c twiceperdayaccordingto labeldirections. Long termstudi eshavenot been performed to evaluat e thecarcinogenic potential oftopical otic dexamethason e. Dexa'!1ethasone hasbeentested forin vitro andin vivo genotoxic potential and showntobe positiveinthefollowingassays: chromosomal aberration s, sister-chromatidexchange inhuman lymphocytes and micronucleiand sister-chromatidexcha nges in mousebone marrow. However,theAmes/Salmon ellaassay, bot h with andwithoutS9mi x, didnot show anyincrease in Hisrevertants. The effect ofdexamethasone onfertilityhasnot beeninvestigated followingtopical otic application. However, thelowest toxic dose ofdexamethasone identif ied followingtopical dermal application was 1. 802 mg/kg in a 26-weekstudy in malerats andresulted In changes to thetestes, epididymi s, spermduct, prostate, seminal vessicle, Cowper' s gland and accessory glands. The relevance ofthisstudy for shortterm topical otic use isunknown.
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